Literature DB >> 3552598

Polymyalgia rheumatica. Its correct diagnosis and treatment.

F D Hart.   

Abstract

Giant cell (temporal) arteritis was first described by Horton and colleagues in 1932, and polymyalgia rheumatica in 1957 by Barber who suggested this title for an entity resembling, but distinct from, rheumatoid arthritis of unknown aetiology in the elderly. Arteritic features were sufficiently common in polymyalgia rheumatica to suggest an arteriopathy as a cause, further evidence of this being the change from the clinical picture picture of polymyalgia rheumatica to giant cell arteritis and vice versa in many patients such that the alternative title polymyalgia arteritica was suggested. The clinical picture of polymyalgia rheumatica is that of an elderly patient, more often female than male, usually over 60 years of age, with painful stiffness in the girdle joints and muscles of the shoulders and hips, but seldom with findings in peripheral or intermediate joints. The painful stiffness in the shoulders, hips and thighs is worse in the early morning. An erythrocyte sedimentation rate over 50mm in 1 hour is usual, and there is a rapid and dramatic response to small doses of corticosteroids (around 10mg prednisolone daily). Arteritic and axial arthritic features have been noted by different authors in different ratios, the disorder gradually abating naturally over periods varying from several months to 7 to 10 years. Deaths, when they occur in this elderly group of patients, have usually been unrelated to the disease or its treatment, but osteoporotic vertebral crush fractures are not uncommon. Partial or complete blindness may occur in patients with either giant cell arteritis or polymyalgia rheumatica, often appearing rapidly after cessation of corticosteroid therapy or rapid reduction of dosage.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552598     DOI: 10.2165/00003495-198733030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

1.  ARTERITIS IN "POLYMYALGIA RHEUMATICA".

Authors:  B HAMRIN; N JONSSON; T LANDBERG
Journal:  Lancet       Date:  1964-02-22       Impact factor: 79.321

2.  THE AETIOLOGY, PATHOLOGY AND COURSE OF GIANT-CELL ARTERITIS. THE POSSIBLE ROLE OF LIGHT SENSITIVITY.

Authors:  P D KINMONT; D I MCCALLUM
Journal:  Br J Dermatol       Date:  1965-04       Impact factor: 9.302

3.  INVOLVEMENT OF LARGE VESSELS IN POLYMYALGIA ARTERITICA.

Authors:  B HAMRIN; N JONSSON; T LANDBERG
Journal:  Lancet       Date:  1965-06-05       Impact factor: 79.321

4.  Polymyalgia rheumatica: a misnomer?

Authors:  E N COOMES; J SHARP
Journal:  Lancet       Date:  1961-12-16       Impact factor: 79.321

5.  Myalgic syndrome with constitutional effects; polymyalgia rheumatica.

Authors:  H S BARBER
Journal:  Ann Rheum Dis       Date:  1957-06       Impact factor: 19.103

6.  Articular and vascular manifestations of polymyalgia rheumatica.

Authors:  M I Bruk
Journal:  Ann Rheum Dis       Date:  1967-03       Impact factor: 19.103

7.  Polymyalgia rheumatica. A manifestation of systemic giant-cell arteritis.

Authors:  K R Wilske; L A Healey
Journal:  Ann Intern Med       Date:  1967-01       Impact factor: 25.391

8.  Visual complications of polymyalgia rheumatica (polymyalgia arteritica).

Authors:  F D Hart
Journal:  Practitioner       Date:  1975-12

9.  The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications.

Authors:  B A Bengtsson; B E Malmvall
Journal:  Arthritis Rheum       Date:  1981-07

10.  Erythrocyte sedimentation rate: the normal range in the elderly.

Authors:  D E Sharland
Journal:  J Am Geriatr Soc       Date:  1980-08       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.